Search research articles
Contact Us
Filters
Showing results (21-30 of 73) with videos related to
Page
of 8
Sort By:
International Journal of Cancer
|
December 15, 1987
Antibody-antigen complex formation following injection of OC125 monoclonal antibody in patients with ovarian cancer
H J Haisma, A Battaile, E W Stradtman, et al.
The Journal of Gene Medicine
|
February 7, 2001
Cationic polymeric gene delivery of beta-glucuronidase for doxorubicin prodrug therapy
M J Fonseca, G Storm, W E Hennink, et al.
Current Gene Therapy
|
October 8, 2003
Protein transduction domains and their utility in gene therapy
A M J Beerens, A F Y Al Hadithy, M G Rots, et al.
International Journal of Molecular Medicine
|
March 29, 2007
Fusion of herpes simplex virus thymidine kinase to VP22 does not result in intercellular trafficking of the protein
A M J Beerens, M G Rots, E F J de Vries, et al.
Cancer Immunology, Immunotherapy : CII
|
January 24, 1998
Construction and characterization of a fusion protein of single-chain anti-carcinoma antibody 323/A3 and human beta-glucuronidase
H J Haisma, R H Brakenhoff, I vd Meulen-Muileman, et al.
Hybridoma
|
August 1, 1995
A monoclonal antibody against human beta-glucuronidase for application in antibody-directed enzyme prodrug therapy
H J Haisma, M Van Muijen, G Scheffer, et al.
Prostate Cancer and Prostatic Diseases
|
December 24, 2002
Transductional targeting of adenoviral vectors to prostate cancer in vitro
C H Bangma, R Kraaij, A Van Rijswijk, et al.
Journal of Drug Targeting
|
January 4, 2008
Secretion of thymidine kinase to increase the effectivity of suicide gene therapy results in the loss of enzymatic activity
A M J Beerens, M G Rots, B Bermúdez, et al.
Biochemical Pharmacology
|
August 9, 1996
Characterization of novel anthracycline prodrugs activated by human beta-glucuronidase for use in antibody-directed enzyme prodrug therapy
P H Houba, R G Leenders, E Boven, et al.
Pharmaceutical Research
|
April 1, 1996
Immunoliposomes as enzyme-carriers (immuno-enzymosomes) for antibody-directed enzyme prodrug therapy (ADEPT): optimization of prodrug activating capacity
M H Vingerhoeds, H J Haisma, S O Belliot, et al.
Page
of 8
Search research articles
Search
Showing results (21-30 of 73) with videos related to
Sort By:
Page
of 8
International Journal of Cancer
|
December 15, 1987
Antibody-antigen complex formation following injection of OC125 monoclonal antibody in patients with ovarian cancer
H J Haisma, A Battaile, E W Stradtman, et al.
The Journal of Gene Medicine
|
February 7, 2001
Cationic polymeric gene delivery of beta-glucuronidase for doxorubicin prodrug therapy
M J Fonseca, G Storm, W E Hennink, et al.
Current Gene Therapy
|
October 8, 2003
Protein transduction domains and their utility in gene therapy
A M J Beerens, A F Y Al Hadithy, M G Rots, et al.
International Journal of Molecular Medicine
|
March 29, 2007
Fusion of herpes simplex virus thymidine kinase to VP22 does not result in intercellular trafficking of the protein
A M J Beerens, M G Rots, E F J de Vries, et al.
Cancer Immunology, Immunotherapy : CII
|
January 24, 1998
Construction and characterization of a fusion protein of single-chain anti-carcinoma antibody 323/A3 and human beta-glucuronidase
H J Haisma, R H Brakenhoff, I vd Meulen-Muileman, et al.
Hybridoma
|
August 1, 1995
A monoclonal antibody against human beta-glucuronidase for application in antibody-directed enzyme prodrug therapy
H J Haisma, M Van Muijen, G Scheffer, et al.
Prostate Cancer and Prostatic Diseases
|
December 24, 2002
Transductional targeting of adenoviral vectors to prostate cancer in vitro
C H Bangma, R Kraaij, A Van Rijswijk, et al.
Journal of Drug Targeting
|
January 4, 2008
Secretion of thymidine kinase to increase the effectivity of suicide gene therapy results in the loss of enzymatic activity
A M J Beerens, M G Rots, B Bermúdez, et al.
Biochemical Pharmacology
|
August 9, 1996
Characterization of novel anthracycline prodrugs activated by human beta-glucuronidase for use in antibody-directed enzyme prodrug therapy
P H Houba, R G Leenders, E Boven, et al.
Pharmaceutical Research
|
April 1, 1996
Immunoliposomes as enzyme-carriers (immuno-enzymosomes) for antibody-directed enzyme prodrug therapy (ADEPT): optimization of prodrug activating capacity
M H Vingerhoeds, H J Haisma, S O Belliot, et al.
Page
of 8